Stay updated on Pembrolizumab in Poor-Prognosis CUP Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Poor-Prognosis CUP Clinical Trial page.

Latest updates to the Pembrolizumab in Poor-Prognosis CUP Clinical Trial page
- Check6 days agoChange DetectedThe record now presents details of the completed Phase 2 pembrolizumab study for patients with poor-prognosis carcinoma of unknown primary site, including its design, eligibility requirements, measured outcomes, and study locations. It also includes posted results-related information and a study protocol document.SummaryDifference47%

- Check13 days agoChange DetectedThe site footer now identifies the platform revision as v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check27 days agoChange DetectedAn NIH-wide banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence.” The site revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check41 days agoChange DetectedThe footer’s ClinicalTrials.gov revision number changed from v3.7.0 to v3.7.1; the study page still displays a 403 error.SummaryDifference0.2%

- Check55 days agoChange DetectedThe study page now displays a 403 Forbidden error instead of the study details, indicating the record is inaccessible at this URL.SummaryDifference18%

- Check62 days agoChange DetectedThe page’s revision tag was updated to v3.7.0, indicating a site or template update. No trial-specific text, dates, or eligibility criteria are affected by this change.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Poor-Prognosis CUP Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Poor-Prognosis CUP Clinical Trial page.